KOSP Kos Pharmaceuticals

First graph, second sentence of release should read: Kos' presentation will take place at 10:00 am PT on Tuesday, May 16, 2006 (sted Kos' presentation will take place at 10:00 am ET on Tuesday, May 16, 2006.). The corrected release reads: KOS ANNOUNCES PRESENTATION AT THE BANK OF AMERICA 2006 HEALTHCARE CONFERENCE Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) today announced that Adrian Adams, President and Chief Executive Officer, will present at the Bank of America 2006 Healthcare Conference, which is being held May 16 - May 18, 2006 in Las Vegas, Nevada. Kos' presentation will take place at 10:00 am PT on Tuesday, May 16, 2006. Interested parties can access the webcast information by going to the investor relations section of Kos' website at www.kospharm.com, and referencing upcoming events. About Kos Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The Company's principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos' strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. Kos has a strong and growing research and development pipeline including proprietary drug delivery technologies in solid-dose, inhalation and aerosol metered-dose device administration to help fuel sustained, organic sales growth into the future. Certain statements in this press release, including statements relating to the Company's strong and growing research and development pipeline and future sales growth are forward-looking and are subject to risks and uncertainties which may cause actual results to differ materially from those projected in a forward-looking statement. These risks and uncertainties include the Company's ability to successfully develop and commercialize new products under development, the Company's ability to enter into new business development and corporate opportunities, the progress of the company's research and development pipeline, the protection afforded by the Company's patents, the effect of conditions in the pharmaceutical industry and the economy in general, and the Company's ability to maintain compliance with FDA. A more detailed discussion of risks attendant to the forward-looking statements included in this press release are set forth in the "Forward-Looking information: Certain Cautionary Statements" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2005, filed with the Securities and Exchange Commission, and in other reports filed with the SEC.